喜炎平与阿维A胶囊联合治疗斑块型银屑病的疗效及其对趋化因子RANTES及MCP-1的影响
|
摘要
目的观察临床应用喜炎平与阿维A胶囊联合治疗斑块型银屑病的疗效及其对趋化因子活化调节蛋白(RANTES)和单核细胞趋化蛋白-1(MCP-1)的影响。方法采用前瞻性研究方法将2015年5月至2017年3月收治146例斑块型银屑病患者随机分为对照组和观察组各73例。对照组给予阿维A胶囊,观察组应用喜炎平与阿维A胶囊联合治疗。对比分析两组患者的临床疗效、RANTES及MCP-1水平和不良反应发生率。结果观察组治疗总有效率(82.2%)明显高于对照组(69.9%),差异有显著性(P<0.05);治疗后两组患者RANTES、MCP-1水平均较治疗前明显下降(P<0.05),观察组下降幅度明显大于对照组(P<0.05);观察组患者用药后不良反应发生率(34.2%)明显低于对照组(50.0%),差异有显著性(P<0.05)。结论临床应用喜炎平与阿维A胶囊联合治疗斑块型银屑病可明显提高治疗效果,改善趋化因子RANTES及MCP-1水平,降低不良反应发生率,值得在临床推广应用。
Objective To observe treatment efficacy of Xi Yan Ping combined with avi A capsule on plaque type psoriasis and its influence on chemokine RANTES and MCP-1. Methods From May 2015 to March 2017,146 patients with plaque psoriasis were randomly divided into the control group and the observation group,with 73 cases in each group. The control group was given avi A capsule,the observation group was given Xi Yan Ping injection combined with avi A capsule. The clinical efficacy,the levels of RANTES and MCP-1 and the incidence of adverse reactions were compared and analyzed between the two groups. Results The total efficiency of the observation group( 82. 2%) was significantly higher than that of the control group( 69. 9%) with significant difference( P < 0. 05). After treatment,RANTES and MCP-1 levels in the two groups were significantly lower than those before treatment( P < 0. 05). The observation group decreased significantly than that in control group( P < 0. 05). The drug adverse reaction rate( 34. 2%) in the observation group was significantly lower than that of the control group( 50%),there was significant difference( P < 0. 05). Conclusion Clinical application of Xi Yan Ping injection combined with avi A capsules in the treatment of plaque psoriasis can significantly improve the therapeutic effect,improve the chemokine RANTES and MCP-1 level,reduce the incidence of adverse reactions,it is worthy of clinical application.
Objective To observe treatment efficacy of Xi Yan Ping combined with avi A capsule on plaque type psoriasis and its influence on chemokine RANTES and MCP-1. Methods From May 2015 to March 2017,146 patients with plaque psoriasis were randomly divided into the control group and the observation group,with 73 cases in each group. The control group was given avi A capsule,the observation group was given Xi Yan Ping injection combined with avi A capsule. The clinical efficacy,the levels of RANTES and MCP-1 and the incidence of adverse reactions were compared and analyzed between the two groups. Results The total efficiency of the observation group( 82. 2%) was significantly higher than that of the control group( 69. 9%) with significant difference( P < 0. 05). After treatment,RANTES and MCP-1 levels in the two groups were significantly lower than those before treatment( P < 0. 05). The observation group decreased significantly than that in control group( P < 0. 05). The drug adverse reaction rate( 34. 2%) in the observation group was significantly lower than that of the control group( 50%),there was significant difference( P < 0. 05). Conclusion Clinical application of Xi Yan Ping injection combined with avi A capsules in the treatment of plaque psoriasis can significantly improve the therapeutic effect,improve the chemokine RANTES and MCP-1 level,reduce the incidence of adverse reactions,it is worthy of clinical application.
引文
[1]辛忠,袁少飞,关敬之.银屑胶囊联合阿维A治疗寻常性银屑病临床观察及其对外周血细胞因子的影响[J].中国皮肤性病学杂志,2016,15(9):988-990.
[2]段振忠.喜炎平与阿维A胶囊联合治疗斑块型银屑病的疗效及其对趋化因子RANTES及MCP-1的影响[J].中国实用医刊,2017,44(11):1047-1048.
[3]赵辩.临床皮肤病学[M].3版.南京:江苏科学技术出版社,2001:759-759.
[4]王晓华,陈力,张璐璐,等.喜炎平注射液治疗寻常型银屑病80例临床疗效观察[J].中医临床研究,2017,9(15):77-78.
[5]刘丽,张杰,郭健,等.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合甲氨蝶呤治疗中重度斑块型银屑病临床观察[J].实用医院临床杂志,2013,10(5):133-135.
[6]刘慧,刘雄彪,汪晓红,等.清热散结片联合阿维A胶囊治疗难治性银屑病的疗效及对炎症反应的影响[J].现代生物医学进展,2017,17(11):2134-2136.
[7]李健华,张玉杰.阿维A对寻常型银屑病患者趋化因子RANTES和MCP-1的影响[J].中华临床医师杂志:电子版,2012,06(5):1217-1220.
[8]于娟.NB-UVB对寻常型银屑病患者外周血CC型趋化因子RANTES及其受体CCR-3mRNA、CCR-5mRNA的影响及意义[J].滨州医学院,2011,15(09):1273-1274.
[9]高梅兰,张玉杰,李玲玲,等.窄谱中波紫外线对银屑病患者单核细胞趋化蛋白-1及其受体CCR2mRNA表达的影响[J].临床皮肤科杂志,2014,43(4):206-209.
[10]王欣.阿维A联合苦参素对老年银屑病患者血清γ-干扰素、白细胞介素-2、肿瘤坏死因子α水平的影响及疗效分析[J].中国卫生检验杂志,2016,12(18):2700-2702.
[11]王俊伟,张斌,高丽,等.银屑胶囊联合阿维A治疗寻常型银屑病患者的疗效及对血清IL-4、IL-10和INF-γ的影响[J].中国中西医结合皮肤性病学杂志,2017,16(2):116-118.
[12]董巧丽,柏金秀,孙东明,等.喜炎平注射液和热毒宁注射液治疗手足口病普通病例的疗效观察[J].临床和实验医学杂志,2012,11(9):686-687.
[13]贾宝珍,郭书萍,刘宏业.阿维A胶囊联合喜炎平治疗斑块型银屑病的临床观察及血清肿瘤坏死因子-α检测[J].中国药物与临床,2016,16(2):181-183.
[2]段振忠.喜炎平与阿维A胶囊联合治疗斑块型银屑病的疗效及其对趋化因子RANTES及MCP-1的影响[J].中国实用医刊,2017,44(11):1047-1048.
[3]赵辩.临床皮肤病学[M].3版.南京:江苏科学技术出版社,2001:759-759.
[4]王晓华,陈力,张璐璐,等.喜炎平注射液治疗寻常型银屑病80例临床疗效观察[J].中医临床研究,2017,9(15):77-78.
[5]刘丽,张杰,郭健,等.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合甲氨蝶呤治疗中重度斑块型银屑病临床观察[J].实用医院临床杂志,2013,10(5):133-135.
[6]刘慧,刘雄彪,汪晓红,等.清热散结片联合阿维A胶囊治疗难治性银屑病的疗效及对炎症反应的影响[J].现代生物医学进展,2017,17(11):2134-2136.
[7]李健华,张玉杰.阿维A对寻常型银屑病患者趋化因子RANTES和MCP-1的影响[J].中华临床医师杂志:电子版,2012,06(5):1217-1220.
[8]于娟.NB-UVB对寻常型银屑病患者外周血CC型趋化因子RANTES及其受体CCR-3mRNA、CCR-5mRNA的影响及意义[J].滨州医学院,2011,15(09):1273-1274.
[9]高梅兰,张玉杰,李玲玲,等.窄谱中波紫外线对银屑病患者单核细胞趋化蛋白-1及其受体CCR2mRNA表达的影响[J].临床皮肤科杂志,2014,43(4):206-209.
[10]王欣.阿维A联合苦参素对老年银屑病患者血清γ-干扰素、白细胞介素-2、肿瘤坏死因子α水平的影响及疗效分析[J].中国卫生检验杂志,2016,12(18):2700-2702.
[11]王俊伟,张斌,高丽,等.银屑胶囊联合阿维A治疗寻常型银屑病患者的疗效及对血清IL-4、IL-10和INF-γ的影响[J].中国中西医结合皮肤性病学杂志,2017,16(2):116-118.
[12]董巧丽,柏金秀,孙东明,等.喜炎平注射液和热毒宁注射液治疗手足口病普通病例的疗效观察[J].临床和实验医学杂志,2012,11(9):686-687.
[13]贾宝珍,郭书萍,刘宏业.阿维A胶囊联合喜炎平治疗斑块型银屑病的临床观察及血清肿瘤坏死因子-α检测[J].中国药物与临床,2016,16(2):181-183.